Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vivus Inc VVUSQ

Healthcare Biotechnology
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic... see more

Recent & Breaking News (OTCPK:VVUSQ)

VIVUS Announces Scientific Presentations

Marketwired May 14, 2015

VIVUS Reports First Quarter 2015 Financial Results

Marketwired May 5, 2015

VIVUS Announces Date of First Quarter 2015 Update and Financial Results Conference Call

GlobeNewswire April 30, 2015

VIVUS Announces New Discount Program Through Sam's Club for Qsymia Patients

Marketwired April 28, 2015

VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia

Marketwired April 21, 2015

VIVUS Files Lawsuit Against Teva for Infringement of Qsymia Patents

Marketwired April 15, 2015

VIVUS to Present at Upcoming Investor Conference

Marketwired April 10, 2015

VIVUS Announces Operational Update

Marketwired March 30, 2015

VIVUS Reports Fourth Quarter and Year-End 2014 Financial Results

Marketwired February 24, 2015

VIVUS to Present at Upcoming Investor Conference

Marketwired February 20, 2015

VIVUS Announces Date of Fourth Quarter and Year End 2014 Update and Financial Results Conference Call

GlobeNewswire February 19, 2015

VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity

Marketwired January 29, 2015

VIVUS to Present at Upcoming Investor Conference

Marketwired January 9, 2015

VIVUS Announces Favorable Formulary Positioning for Qsymia

Marketwired December 15, 2014

VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia

Marketwired November 26, 2014

VIVUS Reports Third Quarter 2014 Financial Results

Marketwired November 5, 2014

VIVUS Announces Qsymia Presentations at Obesity Week 2014

Marketwired November 3, 2014

VIVUS Announces Date of Third Quarter 2014 Update and Financial Results Conference Call

GlobeNewswire October 30, 2014

Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes

Marketwired October 6, 2014

VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity

Marketwired September 18, 2014